The progestin levonorgestrel induces endothelium-independent relaxation of rabbit jugular vein via inhibition of calcium entry and protein kinase C:: role of cyclic AMP

被引:15
作者
Herkert, O
Kuhl, H
Busse, R
Schini-Kerth, VB
机构
[1] Univ Frankfurt Klinikum, Inst Kardiovaskulare Physiol, D-60590 Frankfurt, Germany
[2] Univ Frankfurt Klinikum, Zentrum Frauenheilkunde & Geburtshilfe, D-60590 Frankfurt, Germany
关键词
progestins; vein; protein kinase C; calcium entry; cyclic AMP;
D O I
10.1038/sj.bjp.0703524
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The progestin and oestrogen component of oral contraceptives have been involved in the development of venous thromboembolic events in women. In the present study we determined the vasoactive effects of sex steroids used in oral contraceptives in isolated preconstricted rabbit jugular veins in the presence of diclofenac and examined the underlying mechanisms. 2 The natural hormone progesterone, the synthetic progestins levonorgestrel, 3-keto-desogestrel, gestodene and chlormadinone acetate, and the synthetic estrogen 17 alpha-ethinyloestradiol induced concentration-dependent relaxations of endothelium-intact Veins constricted with U46619. Levonorgestrel also inhibited constrictions evoked by either a high potassium (K+) solution or phorbol myristate acetate (PMA) in the absence and presence of extracellular calcium (Ca2+). In addition, levonorgestrel depressed contractions evoked by Ca2+ and reduced Ca-45(2+) influx in depolarized veins. 3 Relaxations to levonorgestrel in U46619-constricted veins were neither affected by the presence of the endothelium nor by the inhibitor of soluble guanylyl cyclase, NS2028, but were significantly improved either by the selective cyclic AMP phosphodiesterase inhibitor rolipram or in the absence of diclofenac, and decreased by the protein kinase A inhibitor, Rp-8-CPT-cAMPS. Rolipram also potentiated relaxations to levonorgestrel in PMA-constricted veins in the presence, but not in the absence of extracellular Ca2+. Levonorgestrel increased levels of cyclic AMP and inhibited PMA-induced activation of protein kinase C in veins. 4 These findings indicate that levonorgestrel caused endothelium-independent relaxations of jugular veins via inhibition of Ca2+ entry and of protein kinase C activation. In addition, the cyclic AMP effector pathway contributes to the levonorgestrel-induced relaxation possibly by depressing Ca2+ entry.
引用
收藏
页码:1911 / 1918
页数:8
相关论文
共 49 条
[1]   ESTROGEN ACTION VIA THE CAMP SIGNALING PATHWAY - STIMULATION OF ADENYLATE-CYCLASE AND CAMP-REGULATED GENE-TRANSCRIPTION [J].
ARONICA, SM ;
KRAUS, WL ;
KATZENELLENBOGEN, BS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (18) :8517-8521
[2]   ENHANCEMENT BY FACTOR-V LEIDEN MUTATION OF RISK OF DEEP-VEIN THROMBOSIS ASSOCIATED WITH ORAL-CONTRACEPTIVES CONTAINING 3RD-GENERATION PROGESTAGEN [J].
BLOEMENKAMP, KWM ;
ROSENDAAL, FR ;
HELMERHORST, FM ;
BULLER, HR ;
VANDENBROUCKE, JP .
LANCET, 1995, 346 (8990) :1593-1596
[3]   COAGULATION EFFECTS OF ORAL CONTRACEPTION [J].
BONNAR, J .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1987, 157 (04) :1042-1048
[4]   NITRIC-OXIDE ACCOUNTS FOR DOSE-DEPENDENT ESTROGEN-MEDIATED CORONARY RELAXATION AFTER ACUTE ESTROGEN WITHDRAWAL [J].
COLLINS, P ;
SHAY, J ;
JIANG, CW ;
MOSS, J .
CIRCULATION, 1994, 90 (04) :1964-1968
[5]   Antagonistic effects of 17β-estradiol, progesterone, and testosterone on Ca2+ entry mechanisms of coronary vasoconstriction [J].
Crews, JK ;
Khalil, RA .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (04) :1034-1040
[6]   PHARMACOLOGY OF ENDOTHELIN-1 IN ISOLATED VESSELS - EFFECT OF NICARDIPINE, METHYLENE-BLUE, HEMOGLOBIN, AND GOSSYPOL [J].
DORLEANSJUSTE, P ;
FINET, M ;
DENUCCI, G ;
VANE, JR .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1989, 13 :S19-S22
[7]   PROGESTERONE-RECEPTOR AND THE MECHANISM OF ACTION OF PROGESTERONE ANTAGONISTS [J].
EDWARDS, DP ;
ALTMANN, M ;
DEMARZO, A ;
ZHANG, YX ;
WEIGEL, NL ;
BECK, CA .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1995, 53 (1-6) :449-458
[8]   PHARMACOLOGY OF THE POTASSIUM CHANNEL OPENERS [J].
EDWARDS, G ;
WESTON, AH .
CARDIOVASCULAR DRUGS AND THERAPY, 1995, 9 :185-193
[9]  
FARLEY TMM, 1995, LANCET, V346, P1582
[10]  
Gevers Leuven J A, 1987, J Lab Clin Med, V109, P631